Cdex (CDEX) 10-Q 16 Jun 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Apr. 30, 2014	Jun. 11, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'CDEX INC	'
Entity Central Index Key	'0001173738	'
Current Fiscal Year End Date	'--10-31	'
Entity Filer Category	'Smaller Reporting Company	'
Document Type	'10-Q	'
Document Period End Date	30-Apr-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	53,223,458
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Apr. 30, 2014		Oct. 31, 2013
Current assets	'		'
Cash	$117,883	[1]	$98,967
Accounts receivable	16,225	[1]	23,573
Inventory - net	231,950	[1]	240,232
Prepaid expenses and deposits	6,606	[1]	9,108
Total current assets	372,664	[1]	371,880
Property and equipment, net	38,933	[1]	37,889
Patents, net	49,236	[1]	51,559
Other assets	1,399	[1]	1,504
Total assets	462,232	[1]	462,832
Current liabilities	'		'
Accounts payable and accrued expenses	121,181	[1]	8,140
Deferred revenue - current	69,326	[1]	72,985
Total current liabilities	190,507	[1]	81,125
Total liabilities	190,507	[1]	81,125
Commitments and Contingencies	'	[1]	'
Stockholders' equity	'		'
Class A common stock - $.005 par value per share, 300,000,000 shares authorized and 60,223,458 outstanding at April 30, 2014 and 52,946,963 outstanding at October 31, 2013	301,115	[1]	264,732
Additional paid in capital	35,448,505	[1]	35,336,108
Accumulated (deficit)	-35,477,926	[1]	-35,219,164
Total stockholders' equity	271,725	[1]	381,707
Total liabilities and stockholders' equity	462,232	[1]	462,832
Preferred stock - undesignated - $.005 par value per share, 350,000 shares authorized and none outstanding	'		'
Stockholders' equity	'		'
Preferred stock	'	[1]	'
Preferred stock - series A - $.005 par value per share, 150,000 shares authorized and 6,250 outstanding at April 30, 2014 and at October 31, 2013	'		'
Stockholders' equity	'		'
Preferred stock	$31	[1]	$31
[1]	Unaudited

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Apr. 30, 2014		Oct. 31, 2013
Stockholders' equity	'		'
Common stock, par value per share (in Dollars per Share)	$0.01	[1]	$0.01
Common stock, shares authorized (in Shares)	300,000,000	[1]	300,000,000
Common stock, shares outstanding (in Shares)	60,223,458	[1]	52,946,963
Preferred stock - undesignated [Member]	'		'
Stockholders' equity	'		'
Preferred stock, par value per share (in Dollars per Share)	$0.01	[1]	$0.01
Preferred stock, shares authorized (in Shares)	350,000	[1]	350,000
Preferred stock, shares outstanding (in Shares)	0	[1]	0
Preferred stock - series A [Member]	'		'
Stockholders' equity	'		'
Preferred stock, par value per share (in Dollars per Share)	$0.01	[1]	$0.01
Preferred stock, shares authorized (in Shares)	150,000	[1]	150,000
Preferred stock, shares outstanding (in Shares)	6,250	[1]	6,250
[1]	Unaudited

STATEMENTS_OF_OPERATIONS_unaud

STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended		6 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
STATEMENTS OF OPERATIONS [Abstract]	'	'	'	'
Revenue	$50,277	$389,232	$126,284	$428,964
Cost of revenue	6,239	53,153	25,904	69,701
Gross profit	44,038	336,079	100,380	359,263
Operating Expenses	'	'	'	'
Selling, general and administrative	152,769	220,039	274,796	767,165
Research and development	34,596	23,821	91,151	59,545
Total operating expenses	187,365	243,860	365,947	826,710
Income (loss) from operations	-143,327	92,219	-265,567	-467,447
Other income (expense)	'	'	'	'
Other income (expense)	'	29,885	6,805	27,935
Total other income (expense)	'	29,885	6,805	27,935
Net (income) loss	($143,327)	$122,104	($258,762)	($439,512)
Basic net (income) loss per common share (in Dollars per Share)	($0.00)	$0.00	($0.01)	($0.01)
Basic weighted average common shares outstanding (in Shares)	54,344,042	50,982,596	53,645,503	45,403,538

STATEMENTS_OF_CASH_FLOWS_unaud

STATEMENTS OF CASH FLOWS (unaudited) (USD $)	6 Months Ended
	Apr. 30, 2014		Apr. 30, 2013
Cash Flows from Operating Activities	'		'
Net loss	($258,762)		($439,512)
Adjustments to reconcile net loss to cash used by operating activities	'		'
Depreciation and amortization	11,491		15,621
Share-based compensation	8,780		397,125
Gain recognized on the forgiveness of debt	'		-42,539
Changes in operating assets and liabilities	'		'
Accounts receivable	7,348		11,835
Inventory	8,282		-61,215
Deferred costs and other assets	2,607		'
Current liabilities	109,382		-40,321
Net cash used by operating activities	-110,872		-159,006
Cash Flows from Investing Activities	'		'
Purchase of equipment	-10,212		'
Net cash used by investing activities	-10,212		'
Cash Flows from Financing Activities	'		'
Proceeds from warrant exchange offer	140,000		'
Net cash used by financing activities	140,000		'
Net (decrease) in cash	18,916		-159,006
Cash, beginning of the period	98,967		561,858
Cash, end of the period	$117,883	[1]	$402,852
[1]	Unaudited

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Apr. 30, 2014
Basis of Presentation [Abstract]	'
Basis of Presentation	'
	1. Basis of Presentation
	The accompanying interim unaudited condensed financial statements include the accounts of CDEX Inc. as of April 30, 2014.  In the opinion of management, all adjustments (which include normal recurring adjustments) necessary for a fair presentation of the results for the interim periods presented have been made. The results for the three-month and six month periods ended April 30, 2014, may not be indicative of the results for the entire year. The interim unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements contained in our Annual Report on Form 10-K. Our lack of earnings history and continued future losses could adversely affect our financial position and if we are unable to generate funds or obtain funds on acceptable terms, we may not be able to continue operations.
	The accompanying unaudited financial statements are presented pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading.
	Recent Developments
	We have experienced net losses since our inception and, as of April 30, 2014, had an accumulated deficit of approximately $35 million.  We do not expect to have positive cash flow from operations until we have deployed a sufficient number of our ValiMed G4 drug validation systems.  As of April 30, 2014, we had approximately $118,000 in cash provided primarily through proceeds from our Warrant Exchange Offer where we offered to all Warrant holders with an exercise price of $0.10 per share an opportunity to exercise their warrants for $0.02 a share in exchange for the number of shares of common stock issuable under the warrant and a warrant for half the number of shares of common stock issuable under the exercised warrant with an exercise price of $0.15 a share.
	Use of Estimates
	The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management bases its assumptions on historical experiences and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. In addition, management considers the basis and methodology used in developing and selecting these estimates, the trends in and amounts of these estimates, specific matters affecting the amount of and changes in these estimates, and any other relevant matters related to these estimates, including significant issues concerning accounting principles and financial statement presentation. Such estimates and assumptions could change in the future as more information becomes known which could impact the amounts reported and disclosed herein. Significant estimates include revenue recognition, the valuation of inventory and stock-based compensation expense.
	Recent Accounting Pronouncements
	The Company has reviewed, and continues to review, issued accounting pronouncements with the intent of adopting any that are applicable to it. The Company does not expect any recent pronouncements to have an impact on its results of operations or financial position.

Inventory_Net

Inventory - Net	6 Months Ended
	Apr. 30, 2014
Inventory - Net [Abstract]	'
Inventory - Net	'
	2.            Inventory - Net
	Our inventories consisted of the following:
		30-Apr-14			31-Oct-13
	Raw materials	$	200,020		$	170,444
	Finished goods		56,368			94,620
	Subtotal		256,388			265,064
	Obsolescence reserve		(24,438	)		(24,832	)
	Total inventory	$	231,950		$	240,232

Property_and_equipment_net

Property and equipment, net	6 Months Ended
	Apr. 30, 2014
Property and equipment, net [Abstract]	'
Property and equipment, net	'
	3             Property and equipment, net
	Our property and equipment consisted of the following:
		30-Apr-14			31-Oct-13
	Furniture, fixtures and leasehold improvements	$	2,931		$	2,931
	Equipment		605,007			594,795
	Leased equipment		70,654			70,654
	Total		678,592			668,380
	Less accumulated depreciation		(639,659	)		(630,491	)
	Net property and equipment	$	38,933		$	37,889

Patents_net

Patents, net	6 Months Ended
	Apr. 30, 2014
Patents, net [Abstract]	'
Patents, net	'
	4             Patents, net
	Our patents consisted of the following:
		30-Apr-14			31-Oct-13
	Patents	$	100,000		$	100,000
	Less accumulated amortization		(50,764	)		(48,441	)
	Net patents	$	49,236		$	51,559

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	6 Months Ended
	Apr. 30, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
Accounts Payable and Accrued Expenses	'
	5             Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses consisted of the following:
		30-Apr-14		31-Oct-13
	Legal fees	$	4,648	$	240
	Accrued compensation		72,998		625
	Accounts payable		41,160		4,900
	Accrued payable to a distributor		2,375		2,375
		$	121,181	$	8,140

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Apr. 30, 2014
Share-Based Compensation [Abstract]	'
Share-Based Compensation	'
	6.            Share-Based Compensation
	For the three and six months ended April 30, 2014, share-based compensation expense was approximately $9,000, primarily attributable to restricted stock grants issued to our independent Directors under the CDEX Inc. Board Compensation Plan.
	For the three months ended April 30, 2013, share-based compensation expense was approximately $55,000, all of which was attributable to restricted stock grants issued for services. For the six months ended April 30, 2013, share-based compensation expense was approximately $397,000, of which approximately $223,000 was attributable to options, $82,000 was attributable to warrants granted for services and $92,000 was attributable to restricted stock grants issued for services.
	During the six months ended April 30, 2014, 15,000 options were forfeited and approximately 276,000 shares of restricted stock were issued.
	During the three months ended April 30, 2013, 8,350,000 options were granted and 800,000 options were forfeited. During the period, options to purchase 8,000,000 shares of Series A common stock were granted to Mr. Brumfield, the Company’s CEO, with an exercise price of $0.05 a share exercisable for five years from the date of issuance and Mr. Brumfield forfeited the existing 800,000 options granted under his employment agreement. Additionally, options to purchase 150,000 and 200,000 shares of Series A common stock were, respectively, granted to Mr. Stevenson, a director of the Company and to Mr. McCommon, the Company’s CFO. These options have an exercise price of $0.05 a share and are exercisable for five years from the date of issuance.
	We determine the fair value of share-based awards at their grant date, using a Black-Scholes Option Pricing Model applying the assumptions in the following table.  Actual compensation, if any, ultimately realized by option recipients may differ significantly from the amount estimated using an option valuation model.
		For the six months ended April 30,
		2014	2013
	Weighted average grant date fair value	$0.00	$0.06
	Expected volatility	0%	75%
	Expected dividends	0%	0%
	Expected term (years)	-	5
	Risk free rate	-	0.77% - 0.79%
	As of April 30, 2014, there were no unrecognized compensation costs related to unvested restricted stock grants.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Apr. 30, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	7.            Stockholders' Equity
	In February 2014, we issued 92,165 shares to each of our independent Directors under the CDEX Inc. Board Compensation Plan.  In April 2014, we issued 7,000,000 shares of common stock and 3,500,000 warrants to purchase common stock from our Warrant Exchange Offer where we offered to all Warrant holders with an exercise price of $0.10 per share the opportunity to exercise their warrants for $0.02 a share in exchange for the number of shares of common stock issuable under the warrant and a 5-year warrant for half the number of shares of common stock issuable under the exercised warrant with an exercise price of $0.15 a share.
	During the three months ended January 31, 2014, there was no stock activity.  In the three months ended January 31, 2013, as a part of its Plan of Reorganization, the Company issued approximately 37.4 million shares of our Series A common stock and warrants to purchase 33.9 million shares of Series A common stock.  Also, in the three months ended January 31, 2013, as compensation for his efforts as the Company’s Medical Director, the Company issued Jason B. Terrell, 500,000 shares of its Series A common stock and a warrant to purchase 500,000 shares of Series A common stock for $0.10 a share effective for five years.
	In the three months ended April 30, 2013, as a part of its Plan of Reorganization, the Company issued approximately 3.9 million shares of our Series A common stock and warrants to purchase 6.3 million shares of Series A common stock. As a part of this issuance under the Plan of Reorganization, approximately 1.8 million warrants were issued to Mr. Brumfield, the Company’s CEO, with an exercise price of $0.10 a share exercisable for five years from the date of issuance.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Apr. 30, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	8.            Commitments and Contingencies
	Litigation
	We may from time to time be involved in legal proceedings arising from the normal course of business. As of the date of this report, we have not received notice of any other legal proceedings and the Company is not aware of any pending claims or assessments which may have a material adverse impact on the Company’s financial position or results of operations.

Subsequent_Events

Subsequent Events	6 Months Ended
	Apr. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	9. Subsequent Events
	The Company’s management has evaluated subsequent events occurring after April 30, 2014, the date of our most recent balance sheet, through the date our financial statements were issued.  In May 2014, we issued 3,000,000 shares of common stock and 1,500,000 warrants to purchase common stock from our Warrant Exchange Offer where we offered to all Warrant holder with an exercise price of $0.10 per share to exercise their warrants for $0.02 a share in exchange for the number of shares of common stock issuable under the warrant and a 5-year warrant for half the number of shares of common stock issuable under the exercised warrant with an exercise price of $0.15 a share.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Apr. 30, 2014
Basis of Presentation [Abstract]	'
Basis of Presentation, Policy	'
	Basis of Presentation
	The accompanying interim unaudited condensed financial statements include the accounts of CDEX Inc. as of April 30, 2014.  In the opinion of management, all adjustments (which include normal recurring adjustments) necessary for a fair presentation of the results for the interim periods presented have been made. The results for the three-month and six month periods ended April 30, 2014, may not be indicative of the results for the entire year. The interim unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements contained in our Annual Report on Form 10-K. Our lack of earnings history and continued future losses could adversely affect our financial position and if we are unable to generate funds or obtain funds on acceptable terms, we may not be able to continue operations.
	The accompanying unaudited financial statements are presented pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading.
Recent Developments, Policy	'
	Recent Developments
	We have experienced net losses since our inception and, as of April 30, 2014, had an accumulated deficit of approximately $35 million.  We do not expect to have positive cash flow from operations until we have deployed a sufficient number of our ValiMed G4 drug validation systems.  As of April 30, 2014, we had approximately $118,000 in cash provided primarily through proceeds from our Warrant Exchange Offer where we offered to all Warrant holders with an exercise price of $0.10 per share an opportunity to exercise their warrants for $0.02 a share in exchange for the number of shares of common stock issuable under the warrant and a warrant for half the number of shares of common stock issuable under the exercised warrant with an exercise price of $0.15 a share.
Use of Estimates, Policy	'
	Use of Estimates
	The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management bases its assumptions on historical experiences and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. In addition, management considers the basis and methodology used in developing and selecting these estimates, the trends in and amounts of these estimates, specific matters affecting the amount of and changes in these estimates, and any other relevant matters related to these estimates, including significant issues concerning accounting principles and financial statement presentation. Such estimates and assumptions could change in the future as more information becomes known which could impact the amounts reported and disclosed herein. Significant estimates include revenue recognition, the valuation of inventory and stock-based compensation expense.
Recent Accounting Pronouncements, Policy	'
	Recent Accounting Pronouncements
	The Company has reviewed, and continues to review, issued accounting pronouncements with the intent of adopting any that are applicable to it. The Company does not expect any recent pronouncements to have an impact on its results of operations or financial position.

Inventory_Net_Tables

Inventory - Net (Tables)	6 Months Ended
	Apr. 30, 2014
Inventory - Net [Abstract]	'
Schedule of Inventory	'
	Our inventories consisted of the following:
		30-Apr-14			31-Oct-13
	Raw materials	$	200,020		$	170,444
	Finished goods		56,368			94,620
	Subtotal		256,388			265,064
	Obsolescence reserve		(24,438	)		(24,832	)
	Total inventory	$	231,950		$	240,232

Property_and_equipment_net_Tab

Property and equipment, net (Tables)	6 Months Ended
	Apr. 30, 2014
Property and equipment, net [Abstract]	'
Schedule of Property and Equipment	'
	Our property and equipment consisted of the following:
		30-Apr-14			31-Oct-13
	Furniture, fixtures and leasehold improvements	$	2,931		$	2,931
	Equipment		605,007			594,795
	Leased equipment		70,654			70,654
	Total		678,592			668,380
	Less accumulated depreciation		(639,659	)		(630,491	)
	Net property and equipment	$	38,933		$	37,889

Patents_net_Tables

Patents, net (Tables)	6 Months Ended
	Apr. 30, 2014
Patents, net [Abstract]	'
Schedule of Patents	'
	Our patents consisted of the following:
		30-Apr-14			31-Oct-13
	Patents	$	100,000		$	100,000
	Less accumulated amortization		(50,764	)		(48,441	)
	Net patents	$	49,236		$	51,559

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Apr. 30, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
Schedule of Accounts Payable and Accrued Expenses	'
	Accounts payable and accrued expenses consisted of the following:
		30-Apr-14		31-Oct-13
	Legal fees	$	4,648	$	240
	Accrued compensation		72,998		625
	Accounts payable		41,160		4,900
	Accrued payable to a distributor		2,375		2,375
		$	121,181	$	8,140

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Apr. 30, 2014
Share-Based Compensation [Abstract]	'
Schedule of Share-Based Awards, Fair Value Assumptions	'
		For the six months ended April 30,
		2014	2013
	Weighted average grant date fair value	$0.00	$0.06
	Expected volatility	0%	75%
	Expected dividends	0%	0%
	Expected term (years)	-	5
	Risk free rate	-	0.77% - 0.79%

Basis_of_Presentation_Narrativ

Basis of Presentation (Narrative) (Details) (USD $)	6 Months Ended
	Apr. 30, 2014		Oct. 31, 2013	Apr. 30, 2013	Oct. 31, 2012
Basis of Presentation [Abstract]	'		'	'	'
Accumulated deficit	$35,477,926	[1]	$35,219,164	'	'
Cash	$117,883	[1]	$98,967	$402,852	$561,858
Warrant exercise price per share of previously issued warrants (in Dollars per Unit)	'0.10		'	'	'
Exercise price of warrants in exchange for the number of shares of common stock issuable under warrant (in Dollars per Unit)	'0.02		'	'	'
Warrant exercise price of warrant five year warrant offerede for old warrants (in Dollars per Share)	'0.15		'	'	'
[1]	Unaudited

Inventory_Net_Schedule_of_Inve

Inventory - Net (Schedule of Inventory) (Details) (USD $)	Apr. 30, 2014		Oct. 31, 2013
Inventory - Net [Abstract]	'		'
Raw materials	$200,020		$170,444
Finished goods	56,368		94,620
Subtotal	256,388		265,064
Obsolescence reserve	-24,438		-24,832
Total inventory	$231,950	[1]	$240,232
[1]	Unaudited

Property_and_equipment_net_Sch

Property and equipment, net (Schedule of Property Plant and Equipment) (Details) (USD $)	Apr. 30, 2014		Oct. 31, 2013
Property and equipment, net [Abstract]	'		'
Furniture, fixtures and leasehold improvements	$2,931		$2,931
Equipment	605,007		594,795
Leased equipment	70,654		70,654
Total	678,592		668,380
Less accumulated depreciation	-639,659		-630,491
Net property and equipment	$38,933	[1]	$37,889
[1]	Unaudited

Patents_net_Schedule_of_Finite

Patents, net (Schedule of Finite Lived Intangible Assets) (Details) (USD $)	Apr. 30, 2014		Oct. 31, 2013
Patents, net [Abstract]	'		'
Patents	$100,000		$100,000
Less accumulated amortization	-50,764		-48,441
Net patents	$49,236	[1]	$51,559
[1]	Unaudited

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Liabilities) (Details) (USD $)	Apr. 30, 2014		Oct. 31, 2013
Accounts Payable and Accrued Expenses [Abstract]	'		'
Legal fees	$4,648		$240
Accrued compensation	72,998		625
Accounts payable	41,160		4,900
Accrued payable to a distributor	2,375		2,375
Total	$121,181	[1]	$8,140
[1]	Unaudited

ShareBased_Compensation_Narrat

Share-Based Compensation (Narrative) (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2013

Apr. 30, 2013

Apr. 30, 2013

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2013

Stock options [Member]

Stock options [Member]

Stock options [Member]

Stock options [Member]

Stock options [Member]

Stock options [Member]

Restricted stock grants [Member]

Restricted stock grants [Member]

Restricted stock grants [Member]

Warrants [Member]

Chief Executive Officer [Member]

Director [Member]

Chief Financial Officer [Member]

Class A common stock [Member]

Class A common stock [Member]

Class A common stock [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation

$9,000

$8,780

$397,125

'

'

$223,000

'

'

'

$55,000

'

$92,000

$82,000

Unrecognized compensation costs related to unvested restricted stock grants

'

'

'

'

'

'

'

'

'

'

$0

'

'

Options granted during period (in Shares)

'

'

'

8,350,000

'

'

8,000,000

150,000

200,000

'

'

'

'

Options granted, exercise price (in Dollars per Share)

'

'

'

'

'

'

$0.05

$0.05

$0.05

'

'

'

'

Number of shares issued for services (in Shares)

'

'

'

'

'

'

'

'

'

'

276,000

'

'

Number of options forfeited (in Shares)

'

'

'

800,000

15,000

'

'

'

'

'

'

'

'

Maximum exercise period (in Duration)

'

'

'

'

'

'

'P5Y

'P5Y

'P5Y

'

'

'

'

ShareBased_Compensation_Schedu

Share-Based Compensation (Schedule of Share-Based Payment Award Stock Options Valuation Assumptions) (Details) (USD $)	6 Months Ended
	Apr. 30, 2014	Apr. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Weighted average grant date fair value (in Dollars per Share)	$0	$0.06
Expected volatility (in Percent)	0.00%	75.00%
Expected dividends (in Percent)	0.00%	0.00%
Expected term (in Duration)	'	'5 years
Minimum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Minimum risk free rate (in Percent)	'	0.77%
Maximum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Maximum risk free rate (in Percent)	'	0.79%

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details)	6 Months Ended			1 Months Ended				3 Months Ended
	Apr. 30, 2014	Jan. 31, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Feb. 28, 2014	Jan. 31, 2014	Apr. 30, 2013
				Warrant Exchange Offer [Member]	Warrant Exchange Offer [Member]	Warrant Exchange Offer [Member]	Independent Directors [Member]	Medical Director [Member]	Chief Executive Officer [Member]
					Warrants [Member]	Common Stock [Member]	Board Compensation Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Plan of reorganiation, Series A common stock and warrants issued to purchase Series A common stock (in Shares)	'	37,400,000	3,900,000	'	'	'	'	500,000	'
Plan of reorganization, shares of Series A common stock purchased by Series A common stock and warrants issued (in Shares)	'	33,900,000	6,300,000	'	'	'	'	500,000	'
Shares issued (in Shares)	'	'	'	'	3,500,000	7,000,000	92,165	'	'
Warrant exercise price per share (in Dollars per Unit)	'	'	'	'	'	'	'	0.1	0.1
Term of warrant offered in exchange for half the number of shares of common stock issuable under exercised warrant (in Duration)	'	'	'	'5 years	'	'	'	'5 years	'5 years
Warrants issued from warrant exchange offer (in Shares)	'	'	'	'	'	'	'	'	1,800,000
Warrant exercise price per share of previously issued warrants (in Dollars per Unit)	'0.10	'	'	'0.10	'	'	'	'	'
Exercise price of warrants in exchange for the number of shares of common stock issuable under warrant (in Dollars per Unit)	'0.02	'	'	'0.02	'	'	'	'	'
Warrant exercise price of warrant five year warrant offerede for old warrants (in Dollars per Share)	'0.15	'	'	'0.15	'	'	'	'	'

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details)	6 Months Ended
	Apr. 30, 2014
Subsequent Event [Line Items]	'
Warrant exercise price per share of previously issued warrants (in Dollars per Unit)	'0.10
Exercise price of warrants in exchange for the number of shares of common stock issuable under warrant (in Dollars per Unit)	'0.02
Warrant exercise price of warrant five year warrant offerede for old warrants (in Dollars per Share)	'0.15
Warrant Exchange Offer [Member]	'
Subsequent Event [Line Items]	'
Shares issued (in Shares)	3,000,000
Warrants issued from warrant exchange offer (in Shares)	1,500,000
Term of warrant offered in exchange for half the number of shares of common stock issuable under exercised warrant (in Duration)	'5 years
Warrant exercise price per share of previously issued warrants (in Dollars per Unit)	'0.10
Exercise price of warrants in exchange for the number of shares of common stock issuable under warrant (in Dollars per Unit)	'0.02
Warrant exercise price of warrant five year warrant offerede for old warrants (in Dollars per Share)	'0.15